PTO/SB/81 (01-09)

Approved for use through 11/30/2011. OMB 0551-059 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY

OR

App. No./ Patent No. 10/594.992

First Named Inventor B. Michael Longenecker

Filing Date/Issue Date 11/16/06

REVOCATION OF POWER OF ATTORNEY		Title	Mucin	Mucinous glycoprotein (Muc-1) vaccine					
WITH A NEW	Art Unit	1642							
AND		Examiner Name	Branc	Brandon J. Fetterolf					
CHANGE OF CORRESPONDENCE ADDRESS		Atty Docket No./ No.	Conf. 34395	34395-806.201 / 5786					
I hereby revoke all previous powers of attorney given in the above-identified application.									
A Power of Attorney is submitted herewith.									
Number as my/o identified above and Trademark	t Practitioner(s) associated with the following our attorney(s) or agent(s) to prosecute the , and to transact all business in the United S Office connected therewith:	epplication States Patent	ent						
i hereby appoint Practitioner(s) named below as mylour attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith:									
	Practitioner(s) Name		Registration Number						
The address associated with the above-mentioned Customer Number.  OR The address associated with Customer Number:  021971									
Firm or individual Name									
Address									
City		State		Zip					
Country									
Telephone		Email							
Tam the:   Applicant/Inventor. OR   Assignee of record of the entire interest. See 37 CFR 3.71.   Statement under 37 CFR 3.73(b) (Form ₱T DAS \$P\$\$ submitted herewith or filled on									
/ / SIGNATURE of Applicant or Assignee of Record									
Signature	TU VY V		Date	24 June 2010					
Name	Robert/L/ Kirkman, M.D.	Telepho							
Title and Company President/CEO Oncothyreon Inc.									
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.									

This collection of information is required by 37 CPR 1.31, 1.32 and 1.33. The information is required to obtain or retain a bonefit by the public which is to file (and by the USPTO to process) an expectation. Confidentially is governed by 38 U.S.C. 122 and 37 CPR 1.11 and 1.14. The obsection can be used to the USPTO to proceed an expectation of the USPTO to the observation of the USPTO to the Observation of the USPTO to the Observation of the USPTO to the

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

 $\boxtimes$ 

\*Total of 1

forms are submitted.

PTO/SB/96 (07-09)
Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			STATEM	ENT	UNDER 37 CFR 3.73(b)				
Applicant	/Patent Own	er; Oncothyred	n Inc.						
Annileatio	n No./Pater	t No.: 10/594,9	92	File	ed/Issue Date: 11/16/06				
••		glycoprotein (Muc-1		•					
Oncothy	reon Inc.			a_	Delaware corporation				
(Name of As					(Type of Assignee, e.g., corporation, partnership	, university, government agency, etc.)			
states tha	at it is:								
1. 🛛	the assignee of the entire right, title, and interest in;								
2. 🗌	an assignee of less than the entire right, title and interest in (The extent (by percentage) of its ownership interest is%); or								
з. 🔲					ty of (a complete assignment from one	e of the joint inventors was made)			
in the pat	ent applicati	on/patent identified	l above by virtu	e of	either:				
A. 🗌	An assignm	ent from the invent	tor(s) of the pat d Trademark O	ent a	application/patent identified above. The at Reel, Frame, or for which	e assignment was recorded a copy thereof is attached.			
OR B. ⊠					application/patent identified above, to				
	1. From:	B. Michael Long	genecker		To: Biomira Inc.				
		The document was	recorded in the	e Un	ited States Patent and Trademark Off	fice at			
		Reel 0186136	, Frame <u>0551</u>		or for which a copy thereof is attached				
	2 Fmm:	Biomira Inc.			To: Oncothyreon Canada Inc.				
The document was recorded in the United States Patent and Trademark Office at						fice at			
Reel 022420 , Frame 0251 , or for which a copy thereof is attached.									
		Oncothyreon C			To: Oncothyreon Inc.				
	3. From:	The document was	recorded in the	e Un	ited States Patent and Trademark Off	fice at			
					hich a copy thereof is attached.				
		-							
□ /	Additional do	cuments in the cha	in of title are lis	sted	on a supplemental sheet(s).				
As re	equired by 3	7 CFR 3.73(b)(1)(i) being, submitted t	, the document or recordation p	ary e	evidence of the chain of title from the cuant to 37 CFR 3.11.	original owner to the assignee was,			
INIOT	E. A conor	to conville a true	conv of the ori	aina	il assignment document(s)) must be seent in the records of the USPTO. <u>See</u>	ubmitted to Assignment Division In MPEP 302.08]			
The unde	ersigned (wh	ose title is supplied	i below) is auth	orize	ed to act on behalf of the assignee.	24 June 2010			
	Signature					Date			
Ro		kman, M.D.				President/CEO			
- 110		Typed Name				Title			

This collection of information is required by 37 CPR 3.73(b). The information is required to obtain or retain a benefit by the qubble which is to fis (and by the USETO to proceed) an application. Confidentially is governed by 25 U.S.C. 122 and 37 FV. This collection of the process of the pr